An experimental Alzheimer’s drug shows promise targeting a different brain protein, new study shows
The lowest dose cut cognitive decline by 26% in one test, and Biogen plans a larger trial to confirm the effect.
- On Tuesday, researchers reported that experimental drug diranersen slows early Alzheimer's disease by lowering levels of tau protein, marking a markedly different approach from today's amyloid-targeting treatments.
- Tau is one part of a toxic duo fueling Alzheimer's; scientists believe amyloid buildup triggers abnormal tau to form tangles in neurons, though prior attempts to develop tau-targeting drugs have failed.
- Data from the study of about 400 people showed a 26% reduction in cognitive decline with the low dose, which Dr. Cath Mummery of University College London described as "approximately the same" as amyloid drug results.
- Last week, the University of California, San Francisco, opened a first-of-its-kind study known as the Alzheimer's Tau Platform, funded by the National Institutes of Health to test various anti-tau therapies.
- Researchers are exploring whether cholesterol drug obicetrapib mitigates Alzheimer's risk, while Denali Therapeutics CEO Ryan Watts describes using "hitching a ride" with iron to help medicine penetrate the brain's protective lining.
88 Articles
88 Articles
New experimental Alzheimer's drug shows potential after study shows slower cognitive decline
An experimental drug might help slow early Alzheimer’s disease in a markedly different way than today’s treatments — by lowering levels of a brain protein called tau, researchers reported Tuesday. Tau is one part of a toxic duo fueling Alzheimer’s but prior attempts to develop drugs that can target the protein have failed. Two Alzheimer’s drugs, lecanemab and donanemab, try to clear buildup of the better-known amyloid protein and can modestly sl…
An experimental drug could help slow Alzheimer's disease at an early stage in a way that is significantly different from current treatments, by reducing the levels of a brain protein called "tau," researchers announced on Tuesday.
Experimental Alzheimer's drug shows promise targeting a different brain protein, new study shows
An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments – by lowering the brain's production of a protein called tau.
Coverage Details
Bias Distribution
- 74% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
